Edison Pharma Raises $20M to Treat Mitochondrial Disease
November 28, 2012
Share:
Edison Pharmaceuticals, a maker of potential treatments for mitochondrial diseases, has raised $20 million of a planned $35 million Series F round. The financing was led by Mitsui Global Investment, which also obtained a Board seat. With the new capital, Edison will carry out its recently announced 2B clinical trials for treatment of Leigh syndrome and Friedreich’s ataxia.
